H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on BioCardia (BCDA – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $1.99.
Pantginis covers the Healthcare sector, focusing on stocks such as Clene, Shattuck Labs, and Cytokinetics. According to TipRanks, Pantginis has an average return of -0.3% and a 36.87% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCardia with a $9.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
BCDA market cap is currently $39.96M and has a P/E ratio of -2.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Read More on BCDA:
- BCDA Earnings this Week: How Will it Perform?
- BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023
- BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
- BioCardia announces issuance of two patents by USPTO
- BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies